Nautilus Biotechnology Change in Accounts Receivable 2021-2025 | NAUT

Nautilus Biotechnology change in accounts receivable from 2021 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.

Nautilus Biotechnology Change in Accounts Receivable 2021-2025 | NAUT

Nautilus Biotechnology change in accounts receivable from 2021 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$241.7B
Amgen (AMGN)$155.8B
Gilead Sciences (GILD)$149.1B
Vertex Pharmaceuticals (VRTX)$101.5B
Bristol Myers Squibb (BMY)$97.4B
CSL (CSLLY)$86.1B
GSK (GSK)$79.8B
Regeneron Pharmaceuticals (REGN)$59.5B
Alnylam Pharmaceuticals (ALNY)$56.7B
Argenex SE (ARGX)$39.6B
BioNTech SE (BNTX)$27.1B
Insmed (INSM)$26B
Royalty Pharma (RPRX)$20.5B
Biogen (BIIB)$19.8B
Incyte (INCY)$16.8B
Illumina (ILMN)$15.5B
Genmab (GMAB)$14.5B
Genmab (GNMSF)$14.3B
Ascendis Pharma (ASND)$11.7B
BioMarin Pharmaceutical (BMRN)$11.2B
QIAGEN (QGEN)$10.9B
Moderna (MRNA)$10.5B
Exelixis (EXEL)$10.4B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Verona Pharma American Depositary Share (VRNA)$9B
Bio-Techne Corp (TECH)$8.6B
Exact Sciences (EXAS)$8.5B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.1B
Halozyme Therapeutics (HALO)$8B